Wednesday, November 01, 2023 7:43:02 PM
ABVC BioPharma: A Comprehensive Guide To Discover The True Value Of Your Shares:
11/01/2023 7:45 P.M.
Key Highlights
• ABVC Biopharma has gained interest in the investment community due to strategic partnerships in neurological and mental health treatments.
• The company's CNS drugs targeting MDD and ADHD have definitive agreements and a licensing deal, with potential income of $20 million and a valuation of $667 million.
• ABVC's flagship product, Vitargus®, is expected to be the first biodegradable hydrogel product used in retinal detachment surgery, with positive results potentially leading to distribution agreements in Asia and Australia.
The story of a company changing the way we treat diseases
ABVC BioPharma, Inc. (NASDAQ: ABVC ), is a clinical-stage biopharmaceutical company with the aim of transforming the oncology/hematology, CNS disorders, and ophthalmology treatment landscape with healthier and innovative therapies with better odds at a positive outcome.
Pioneering the future of neurological and mental health treatments
ABVC Biopharma Inc. has recently gained interest in the investment community. The stock surged by 300% and then retreated on Thursday October 26, 2023 following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. ABVC is excited about its major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive the multi-product biopharma company forward. ABVC has definitive agreements for the same CNS drugs with Xinnovation for ABV-1504, ABV-1505, and ABV-1601. The licensing deal carries a possible aggregate income of $20 million for ABVC. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. Xinnovation will fund the Phase III trials under the agreement and ABVC gets the global market less the Chinese market.
Xinnovation Therapeutics Co., Ltd. is headquartered in Hangzhou, China, with offices in the United States & Europe. The company has raised over $100 million in funding from leading investors, including Sequoia Capital China, Hillhouse Capital, & OrbiMed.
The ABVC collaboration holds immense potential for both companies.
ABVC, anticipates substantial royalty payments ranging from 5% to 12% based on the projected annual net sales of the licensed drugs in China. The deal could generate approximately $50 million annual revenue for ABVC, with an estimated revenue of $1 billion during the patent life of these products, could be achieved. Figures highlight the Chinese market potential.
ABVC's CNS drugs have been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which ABVC expects to complete by the end of 2023.
Vitargus®: A revolutionary hydrogel product for retinal detachment surgery
In ophthalmology, Vitargus® (ABV-1701) is a groundbreaking, advanced-staged and ABVC's flagship product that is expected to be the first biodegradable hydrogel product used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next phase of the trial in two participating sites.
The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. This project is proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation.
The Phase II trial of Vitargus® is expected to release its results in Q4 2023. If the results are positive, it could lead to distribution agreements in Asia and Australia in early 2024.
According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven, in part, by the rising geriatric population worldwide.
Early clinical studies done by the Company indicate Vitargus® has unique properties that could eliminate the need for patients to remain in a face-down position post-surgery, while significantly improving patient comfort and visual acuity during surgical recovery compared to current products available on the market. Vitargus® is believed to be the first biodegradable vitreous substitute to eliminate the need for an additional surgery to remove surgical fluids.Several large pharmaceutical companies are interested in becoming distribution and/or manufacturing partners for Vitargus®. ABVC continues to have active discussions.
FDA approves clinical trial of BLEX 404 for Advanced Non-Small Cell Lung Cancer
The U.S. FDA has approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519. This treatment is being co-developed by BioKey, Inc. and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. With three previous INDs approved by the US FDA for combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer, BLEX 404 is a promising new option in the fight against cancer.
Financial report with forward progress
ABVC BioPharma is making significant strides in its clinical trials and pipeline development thus creating a more financially sound company going forward under an experienced CEO. The company generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively, representing an increase of $613,986 or approximately 173%.Despite a net loss of $16,312,374 for the year ended December 31, 2022 compared to $12,035,851 for the year ended December 31, 2021, ABVC BioPharma has received a $3.175 million investment from The Lind Partners to continue clinical trials. This investment will help the company to further develop its pipeline of six drugs and one medical device known as Vitargus®, a biodegradable vitreous substitute that facilitates retina reattachment surgery.
ABVC signed both an agreement with Xinnovation and a term sheet with AiBtl BioPharma to earn licensing fees of up to $20 million from Xinnovation and royalties of 5-12% of net sales from AiBtl BioPharma. The licensed products in the term sheet with AiBtl BioPharma for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD) were valued at $667 million by a third-party evaluation. The new CEO of ABVC has chosen to forgo a salary and instead opted for stock options as a pivotal component of his compensation package. This move demonstrates the CEO’s confidence in the company’s future and its potential for growth.The future financial outlook looks to be improving dramatically for ABVC BioPharma with the flagship product Vitargus® expected to find cash infusion collaboration deals in the near future.
Forging powerful alliances with strategic partners to unlock new opportunities and drive growth
1) BioKey, Inc., a leading producer of dietary supplements in its GMP facility, is set to receive USD $1.0 million from Define Biotech Co. Ltd. amid increasing interest in mushroom-based nutritional supplements. Define Biotech has been granted the right to distribute the nutritional supplement containing Maitake mushrooms in China and Taiwan. Provides contract development and manufacturing services
.2) MerDury BioPharma for New Product Development and Commercialization through BioKey, Inc. collaborative agreement
3) Ramathibidi Hospital in Thailand. Update on Phase II site initiation
4) Srinagarind Hospital in Thailand Vitargus® meeting to discuss Phase II study protocol with the principal investigator and begin training clinical personnel. Agreement Update on Phase II site initiation
5) Sydney Eye Hospital in Australia Receives ethical approval
6) Cedars-Sinai Medical Center conducts some of the studies Phase I study treating depression
7) Rgene Corporation, Taiwan. Co-development partnership
8) AiBtl BioPharma $667 million deal Best Stocks. AiBtl is an American company and intends to go public on NASDAQ in 2024.
9) Xinnovation Licensing agreement Exclusive licensing agreement in China
10) Science Park Administration in Taiwan creating production facility
11) Zhonghui United Technology (Chengdu) Group Co., Ltd Cooperation Agreement to exchange a 20% ownership stake. Do not underestimate the culture for "healthy medicines" in China and all of Asia.
The list of strategic partnerships mentioned above is just the tip of the iceberg. The extensive network of partners is constantly growing and evolving to provide a bright future for investors and customers..
Video investors should not miss
The final word
ABVC Biopharma Inc. is a promising investment with multiple near-term catalysts. The company’s strategic partnerships in neurological and mental health treatments create a promising future. ABVC’s CNS drugs targeting MDD and ADHD have definitive agreements with Xinnovation for ABV-1504, ABV-1505 and ABV-1601, The definitive agreement carries a possible aggregate income of $20 million for ABVC. There is also a licensing deal with AiBtl BioPharma for a valuation of $667 million. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. ABVC’s CNS drug has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
Investors should keep an eye on ABVC’s major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC has commenced ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. With all these developments in place, ABVC Biopharma Inc. is poised to make a significant impact in the biopharmaceutical industry. ABVC Biopharma shares could revalue upwards of $35 in 12 months, given the transformational leadership of the current CEO and his team.
Information concerning the derived price projection
The Marketing Sentinel Share price expected to rise
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet Buying while staying silent?
Previously Zacks had a $9.50 valuation before the current news releases.
Zacks reports a $20.20 price target from an analyst $20.20
Given the current direction of ABVC Biopharma under the leadership of its CEO, a $35 share projection in 12 months seems justified.
11/01/2023 7:45 P.M.
Key Highlights
• ABVC Biopharma has gained interest in the investment community due to strategic partnerships in neurological and mental health treatments.
• The company's CNS drugs targeting MDD and ADHD have definitive agreements and a licensing deal, with potential income of $20 million and a valuation of $667 million.
• ABVC's flagship product, Vitargus®, is expected to be the first biodegradable hydrogel product used in retinal detachment surgery, with positive results potentially leading to distribution agreements in Asia and Australia.
The story of a company changing the way we treat diseases
ABVC BioPharma, Inc. (NASDAQ: ABVC ), is a clinical-stage biopharmaceutical company with the aim of transforming the oncology/hematology, CNS disorders, and ophthalmology treatment landscape with healthier and innovative therapies with better odds at a positive outcome.
Pioneering the future of neurological and mental health treatments
ABVC Biopharma Inc. has recently gained interest in the investment community. The stock surged by 300% and then retreated on Thursday October 26, 2023 following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. ABVC is excited about its major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive the multi-product biopharma company forward. ABVC has definitive agreements for the same CNS drugs with Xinnovation for ABV-1504, ABV-1505, and ABV-1601. The licensing deal carries a possible aggregate income of $20 million for ABVC. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. Xinnovation will fund the Phase III trials under the agreement and ABVC gets the global market less the Chinese market.
Xinnovation Therapeutics Co., Ltd. is headquartered in Hangzhou, China, with offices in the United States & Europe. The company has raised over $100 million in funding from leading investors, including Sequoia Capital China, Hillhouse Capital, & OrbiMed.
The ABVC collaboration holds immense potential for both companies.
ABVC, anticipates substantial royalty payments ranging from 5% to 12% based on the projected annual net sales of the licensed drugs in China. The deal could generate approximately $50 million annual revenue for ABVC, with an estimated revenue of $1 billion during the patent life of these products, could be achieved. Figures highlight the Chinese market potential.
ABVC's CNS drugs have been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which ABVC expects to complete by the end of 2023.
Vitargus®: A revolutionary hydrogel product for retinal detachment surgery
In ophthalmology, Vitargus® (ABV-1701) is a groundbreaking, advanced-staged and ABVC's flagship product that is expected to be the first biodegradable hydrogel product used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next phase of the trial in two participating sites.
The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. This project is proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation.
The Phase II trial of Vitargus® is expected to release its results in Q4 2023. If the results are positive, it could lead to distribution agreements in Asia and Australia in early 2024.
According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven, in part, by the rising geriatric population worldwide.
Early clinical studies done by the Company indicate Vitargus® has unique properties that could eliminate the need for patients to remain in a face-down position post-surgery, while significantly improving patient comfort and visual acuity during surgical recovery compared to current products available on the market. Vitargus® is believed to be the first biodegradable vitreous substitute to eliminate the need for an additional surgery to remove surgical fluids.Several large pharmaceutical companies are interested in becoming distribution and/or manufacturing partners for Vitargus®. ABVC continues to have active discussions.
FDA approves clinical trial of BLEX 404 for Advanced Non-Small Cell Lung Cancer
The U.S. FDA has approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519. This treatment is being co-developed by BioKey, Inc. and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. With three previous INDs approved by the US FDA for combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer, BLEX 404 is a promising new option in the fight against cancer.
Financial report with forward progress
ABVC BioPharma is making significant strides in its clinical trials and pipeline development thus creating a more financially sound company going forward under an experienced CEO. The company generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively, representing an increase of $613,986 or approximately 173%.Despite a net loss of $16,312,374 for the year ended December 31, 2022 compared to $12,035,851 for the year ended December 31, 2021, ABVC BioPharma has received a $3.175 million investment from The Lind Partners to continue clinical trials. This investment will help the company to further develop its pipeline of six drugs and one medical device known as Vitargus®, a biodegradable vitreous substitute that facilitates retina reattachment surgery.
ABVC signed both an agreement with Xinnovation and a term sheet with AiBtl BioPharma to earn licensing fees of up to $20 million from Xinnovation and royalties of 5-12% of net sales from AiBtl BioPharma. The licensed products in the term sheet with AiBtl BioPharma for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD) were valued at $667 million by a third-party evaluation. The new CEO of ABVC has chosen to forgo a salary and instead opted for stock options as a pivotal component of his compensation package. This move demonstrates the CEO’s confidence in the company’s future and its potential for growth.The future financial outlook looks to be improving dramatically for ABVC BioPharma with the flagship product Vitargus® expected to find cash infusion collaboration deals in the near future.
Forging powerful alliances with strategic partners to unlock new opportunities and drive growth
1) BioKey, Inc., a leading producer of dietary supplements in its GMP facility, is set to receive USD $1.0 million from Define Biotech Co. Ltd. amid increasing interest in mushroom-based nutritional supplements. Define Biotech has been granted the right to distribute the nutritional supplement containing Maitake mushrooms in China and Taiwan. Provides contract development and manufacturing services
.2) MerDury BioPharma for New Product Development and Commercialization through BioKey, Inc. collaborative agreement
3) Ramathibidi Hospital in Thailand. Update on Phase II site initiation
4) Srinagarind Hospital in Thailand Vitargus® meeting to discuss Phase II study protocol with the principal investigator and begin training clinical personnel. Agreement Update on Phase II site initiation
5) Sydney Eye Hospital in Australia Receives ethical approval
6) Cedars-Sinai Medical Center conducts some of the studies Phase I study treating depression
7) Rgene Corporation, Taiwan. Co-development partnership
8) AiBtl BioPharma $667 million deal Best Stocks. AiBtl is an American company and intends to go public on NASDAQ in 2024.
9) Xinnovation Licensing agreement Exclusive licensing agreement in China
10) Science Park Administration in Taiwan creating production facility
11) Zhonghui United Technology (Chengdu) Group Co., Ltd Cooperation Agreement to exchange a 20% ownership stake. Do not underestimate the culture for "healthy medicines" in China and all of Asia.
The list of strategic partnerships mentioned above is just the tip of the iceberg. The extensive network of partners is constantly growing and evolving to provide a bright future for investors and customers..
Video investors should not miss
The final word
ABVC Biopharma Inc. is a promising investment with multiple near-term catalysts. The company’s strategic partnerships in neurological and mental health treatments create a promising future. ABVC’s CNS drugs targeting MDD and ADHD have definitive agreements with Xinnovation for ABV-1504, ABV-1505 and ABV-1601, The definitive agreement carries a possible aggregate income of $20 million for ABVC. There is also a licensing deal with AiBtl BioPharma for a valuation of $667 million. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. ABVC’s CNS drug has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
Investors should keep an eye on ABVC’s major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC has commenced ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. With all these developments in place, ABVC Biopharma Inc. is poised to make a significant impact in the biopharmaceutical industry. ABVC Biopharma shares could revalue upwards of $35 in 12 months, given the transformational leadership of the current CEO and his team.
Information concerning the derived price projection
The Marketing Sentinel Share price expected to rise
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet Buying while staying silent?
Previously Zacks had a $9.50 valuation before the current news releases.
Zacks reports a $20.20 price target from an analyst $20.20
Given the current direction of ABVC Biopharma under the leadership of its CEO, a $35 share projection in 12 months seems justified.
Recent ABVC News
FEATURED DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM
